Neuren Pharmaceuticals Limited (ASX:NEU)
Australia · Delayed Price · Currency is AUD | Market Cap | 3.00B +26.6% |
| Revenue (ttm) | 69.53M -68.2% |
| Net Income | 20.26M -86.4% |
| EPS | 0.16 -86.4% |
| Shares Out | 126.77M |
| PE Ratio | 151.75 |
| Forward PE | 46.15 |
| Dividend | 0.30 (1.27%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 373,546 |
| Open | 24.11 |
| Previous Close | 23.96 |
| Day's Range | 23.50 - 24.11 |
| 52-Week Range | 11.00 - 24.55 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 27.03 (+14.24%) |
| Est. Earnings | Nov 26, 2026 |
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo... [Read more]
Financial Performance
In 2025, Neuren Pharmaceuticals's revenue was 64.65 million, a decrease of -70.18% compared to the previous year's 216.83 million. Earnings were 30.44 million, a decrease of -78.57%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for NEU stock is "Strong Buy." The 12-month stock price target is $27.03, which is an increase of 14.24% from the latest price.
News
Neuren Pharmaceuticals Shares Soar as Daybue Sales Surge and Royalty Guidance Jumps on US$35 Million Milestone
Neuren Pharmaceuticals shares rose nearly 17% after stronger Daybue sales and a US$35 million milestone payment prompted the company to raise its 2026 royalty income guidance.
Neuren Pharmaceuticals Earnings release: Q3 2026
Neuren Pharmaceuticals released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
FDA Grants Neuren's NNZ-2591 Orphan Drug Designation For Newborn Encephalopathy
(RTTNews) - Neuren Pharmaceuticals Ltd. (NEU.AX) said Monday the U.S. Food and Drug Administration granted orphan drug designation to NNZ-2591 for neonatal hypoxic-ischemic encephalopathy.
Neuren Pharmaceuticals Shares Jump 6% as Investors Eye Japan Trial Readout and European Launch of Rett Drug
Neuren Pharmaceuticals shares gained 6.3% as investors focused on potential milestone payments, DAYBUE sales growth, European expansion and upcoming Japanese trial results for trofinetide.
Neuren Pharmaceuticals Earnings Call Transcript: H1 2026
Robust cash reserves and strong DAYBUE royalty income enabled a new dividend program, while European approval and U.S. sales momentum drive growth. NNZ-2591's phase III KOALA trial is progressing well, with multiple regulatory and commercial catalysts ahead.
Neuren Pharmaceuticals Quarterly report: H1 2026
Neuren Pharmaceuticals has published its H1 2026 quarterly earnings report on August 25, 2026.
Neuren Pharmaceuticals Earnings release: H1 2026
Neuren Pharmaceuticals released its H1 2026 earnings on August 25, 2026, summarizing the period's financial results.
Neuren Pharmaceuticals Slides: H1 2026
Neuren Pharmaceuticals has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 25, 2026.
Neuren Pharmaceuticals Transcript: AGM 2026
Strong financial growth driven by DAYBUE royalties and expanding U.S. market presence was highlighted, with strategic focus on advancing NNZ-2591 clinical trials and exploring new indications. Dividend policy and capital management remain under review, while regulatory and market challenges were openly discussed.
Neuren Pharmaceuticals Annual report: H2 2025
Neuren Pharmaceuticals has published its H2 2025 annual report on February 27, 2026.
Neuren Pharmaceuticals Earnings release: H2 2025
Neuren Pharmaceuticals released its H2 2025 earnings on February 27, 2026, summarizing the period's financial results.
Neuren Pharmaceuticals Transcript: Investor update
A new share buyback of up to 5% was approved, reflecting strong financials and confidence in future growth. Key clinical programs for PMS, Pitt Hopkins, and HIE are prioritized, with PMS phase III now underway and additional studies targeted for late 2024. Management remains focused on orphan indications and sees recent share price volatility as disconnected from fundamentals.
Neuren Pharmaceuticals Press release: Investor update
Neuren Pharmaceuticals issued a press release on February 11, 2026, disclosing material business information to investors.
Neuren Pharmaceuticals upgraded to Buy from Hold at Jefferies
Jefferies analyst David Stanton upgraded Neuren Pharmaceuticals to Buy from Hold with a price target of A$16.75, up from A$11.20. Acadia acquired ex-North American rights to trofinetide and global rig...